In a filing, Enliven Therapeutics Inc revealed its Officer Hohl Benjamin acquired Company’s shares for reported $59980.0 on Jun 13 ’25. In the deal valued at $19.99 per share,3,000 shares were bought.
Then, Patel Anish sold 6,667 shares, generating $135,574 in total proceeds. Upon selling the shares at $20.34, the CHIEF OPERATING OFFICER now owns 303,309 shares.
Before that, Patel Anish bought 6,667 shares. Enliven Therapeutics Inc shares valued at $138,274 were divested by the Officer at a price of $20.74 per share.
Goldman initiated its Enliven Therapeutics Inc [ELVN] rating to a Buy in a research note published on June 16, 2025; the price target was $37. A number of analysts have revised their coverage, including BTIG Research’s analysts, who began to cover the stock in mid December with a ‘”a Buy”‘ rating. H.C. Wainwright began covering ELVN with “Buy” recommendation on September 09, 2024. Robert W. Baird started covering the stock on June 11, 2024. It rated ELVN as “an Outperform”.
Price Performance Review of ELVN
On Monday, Enliven Therapeutics Inc [NASDAQ:ELVN] saw its stock jump 5.39% to $23.09. Over the last five days, the stock has gained 13.52%. Enliven Therapeutics Inc shares have risen nearly 2.62% since the year began. Nevertheless, the stocks have risen 1.49% over the past one year. While a 52-week high of $30.03 was reached on 01/03/25, a 52-week low of $13.30 was recorded on 04/10/25.
Levels Of Support And Resistance For ELVN Stock
The 24-hour chart illustrates a support level at 22.16, which if violated will result in even more drops to 21.24. On the upside, there is a resistance level at 24.06. A further resistance level may holdings at 25.04.
The most recent change occurred on April 09, 2024 when Mizuho began covering the stock and recommended ‘”a Buy”‘ rating along with a $34 price target.
